Description

Insulin Detemir is a man-made, long-acting insulin analogue designed for basal glucose control in research models. It features a fatty acid (myristic acid) bound to the Lys-B29 position, improving albumin binding for prolonged duration (up to ~24 h) and reduced variability. Its recombinant origin ensures consistent quality. Made in a GMP-compliant facility and supplied with purity ?95.0%, Insulin Detemir is ideal for laboratory investigations of insulin action, glucose metabolism, and pharmaceutical formulation studies. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Insulin Detemir acts by binding to insulin receptors, lowering hepatic glucose output and enhancing peripheral glucose uptake. Its myristic acid modification enhances albumin binding, extending its action and reducing between-dose variability—typically lasting up to 24 hours. It’s extensively used in in vitro and animal studies of basal insulin dynamics, pharmacokinetics, microphysiological modeling, and formulation testing. Intended for laboratory research use only.

Side Effects (For Reference Only in Models)

In experimental systems, high concentrations of Insulin Detemir may cause hypoglycemic events in cell or tissue models. Injection-site reactions or altered cellular metabolism may be observed in animal studies. These observations are for modeling context only and do not translate to clinical safety assessments—for laboratory research use only.

Disclaimer

Insulin Detemir is supplied for laboratory research use only. It is not intended for diagnostic, clinical, veterinary, or therapeutic use. All handling should comply with institutional safety and disposal protocols.